Nevirapine Levels and Fluconazole
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130317081552im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Nevirapine (NVP)-based antiretroviral therapy (ART) has been commonly used in many developing countries due to its affordability and feasibility. Nonetheless, the potential drug-drug interaction between NVP and fluconazole (FLU) is a major concern. NVP can induce cytochrome P450 isoenzymes in the liver while FLU inhibit the activity of this enzyme. The recent report has demonstrated that fluconazole significantly raises plasma NVP levels and may cause serious hepatotoxicity. Conversely, NVP does not significantly influence the plasma level of FLU. However, there have not been enough data or any recommendations to adjust NVP dosage for the concurrent use of both drugs in order to avoid the adverse events. A previous study has demonstrated that genetic disposition may play a role in NVP hypersensitivity reactions. There is little data of safety and tolerability for concurrent use of NVP and FLU in Asian populations. We therefore conducted this prospective observational study to compare the trough plasma NVP levels and frequencies of adverse events among antiretroviral HIV-infected patients who did not receive FLU and received FLU in different dosages for cryptococcosis prophylaxis or treatment; and subsequently received NVP-based ART regimens.
Condition |
---|
Nevirapine Fluconazole Adverse Event |
Study Type: | Observational |
Study Design: | Observational Model: Defined Population Time Perspective: Longitudinal Time Perspective: Prospective |
Official Title: | Plasma Nevirapine Levels and Adverse Events Among HIV-Infected Patients Concurrently Receiving Nevirapine-Based Antiretroviral Therapy and Fluconazole |
![](https://webarchive.library.unt.edu/web/20130317081552im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 15 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-infected patients >15 years of age,
- naïve to antiretroviral therapy,
- were initiated with a NVP-based ART regimen,
- used NVP 200-mg once-daily lead-in dose, prior to escalation to 200 mg twice daily.
Exclusion Criteria:
- creatinine level was higher than 2.0 mg/ml
- liver aminotransferase enzyme was higher than five times of upper normal limit
- receiving a medication that has drug-drug interactions with NVP or FLU
![](https://webarchive.library.unt.edu/web/20130317081552im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
![](https://webarchive.library.unt.edu/web/20130317081552im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
ClinicalTrials.gov Identifier: | NCT00309582 History of Changes |
Other Study ID Numbers: | BIR2405 |
Study First Received: | March 30, 2006 |
Last Updated: | March 30, 2006 |
Health Authority: | Thailand: Ministry of Public Health |
Additional relevant MeSH terms:
Fluconazole Nevirapine Antifungal Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions 14-alpha Demethylase Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |
ClinicalTrials.gov processed this record on March 14, 2013